Gerresheimer’s Accounting Quagmire Swallows a €10 Million Insider Vote of Confidence

Germany's regulator and APAS probe Gerresheimer's accounting; activist Active Ownership Capital raises stake to 15% amid 60% market value loss. Company secures debt relief, plans US unit sale.

Germany’s financial regulator and an independent audit oversight body have both opened probes into Gerresheimer’s accounting practices, ensnaring the medical packaging specialist in a crisis that has erased nearly 60% of its market value over the past year. While the company battles to restore trust, its largest shareholder has doubled down with a €10 million bet that the wreckage is overdone.

Active Ownership Capital, the activist investment firm that has long pressed for strategic change at the Neuss-based group, acquired more than 100,000 shares in early May through multiple tranches. The buying spree pushed its total stake past the 15% threshold – a powerful signal from an insider with skin in the game. Yet the market has so far shrugged. Gerresheimer’s stock closed at €24.92 on Friday, capping a weekly loss of nearly 9% and leaving the shares deep in technically oversold territory with a 14-day relative strength index of 28.1.

Behind the sell-off lies a thicket of governance problems. The company postponed the release of its audited 2025 financial statements for a second time, now targeting June. The delay stems from an internal investigation into booking irregularities: Gerresheimer recognised revenue by invoicing customers for goods that had not yet been shipped, a practice that Art. 60 of the German Commercial Code explicitly prohibits. The audit watchdog APAS has since launched proceedings against KPMG, Gerresheimer’s long-standing auditor, while the Federal Financial Supervisory Authority (BaFin) is scrutinising misstated leasing liabilities to the tune of roughly €65 million, as well as questionable capitalisation of development costs.

The fallout has been brutal. The stock briefly crashed 38% from its pre-scandal levels, and the company was kicked out of the SDAX index in April after failing to deliver its audited accounts on time. Although the analyst consensus still rates Gerresheimer a “hold” with an average price target of €34.17 – a 37% premium to current levels – the persistent absence of verified numbers has hollowed out institutional credibility.

In an effort to stabilise the ship, management secured a crucial concession from its lenders. Banks and Schuldschein note holders have extended the deadline for the audited financials to the end of September 2026 and temporarily waived key leverage covenants until then. This breathing room gives Gerresheimer until late next year to clean up its balance sheet and restore compliance. A more immediate lifeline is the planned sale of its US subsidiary Centor, which serves the pharmacy packaging market. The disposal, expected to close before year-end, will shed a non-core unit and help reduce net debt.

On the operational front, Gerresheimer still targets full-year 2026 revenue of up to €2.4 billion. The company also showcased a new packaging innovation at the Interpack trade fair last week: LeneX UltraGuard, developed jointly with Milliken & Company, claims to cut moisture penetration in HDPE containers by as much as 40% – a product differentiator that could bolster the core medical packaging franchise. Yet until the June release of the audited annual report and first-quarter figures, followed by the half-year statement due 14 July, every product launch will struggle to drown out the noise from Frankfurt and Bonn.

The activist shareholder sees opportunity where others see only risk. Active Ownership Capital, which has long urged a radical restructuring, believes the group holds substantial value trapped beneath the governance turmoil. For the stock to recapture lost ground, however, Gerresheimer must first demonstrate that its internal controls are watertight and that the BaFin probe will not yield further sanctions. The June accounts represent the first hard catalyst: either they convince the market that the worst is over, or they deepen the crisis of confidence that has already wiped out more than half of the company’s equity in twelve months.